Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006247 · ClinicalTrials.gov registry record · Phase 2
Early Parkinson's Disease Monotherapy With CVN424
A Phase 2 study of Parkinson's Disease, sponsored by Cerevance Beta.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT06006247 is a Phase 2 study of Parkinson's Disease that has completed, run by Cerevance Beta. The registered enrollment target is 64 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06006247, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Cerevance Beta.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CVN424 150 mg
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- SFM Clinical Research, LLC - Boca Raton
- N1 Research LLC - Orlando
- Parkinson's Disease Treatment Center of SWFL - Port Charlotte
- University of South Florida Parkinson's Disease and Movement Disorders Center - Tampa
Arizona
- Barrow Neurological Institute - Phoenix
- St Joseph's Hospital and Medical Center - Phoenix
- Muhammad Ali Parkinson Center - Phoenix
- Movement Disorders Center of Arizona, LLC - Scottsdale
Michigan
- University of Michigan Hospital / Michigan Clinical Research Unit (MCRU) Cardiovascular Center - Ann Arbor
- University of Michigan Department of Neurology - Ann Arbor
- Quest Research Institute - Farmington Hills
Kentucky
- University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research - Lexington
- University of Kentucky, Center for Clinical and Translational Sciences - Lexington
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Georgia
- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2025-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06006247
The ClinicalTrials.gov registry entry for NCT06006247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (90% lower). The listed sponsor is Cerevance Beta, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06006247 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Arizona, Michigan.
Frequently Asked Questions
What is clinical trial NCT06006247 about?
NCT06006247 is a clinical study titled "Early Parkinson's Disease Monotherapy With CVN424". This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on mo...
What is the current status of trial NCT06006247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-09-11. Estimated completion is 2025-02-13.
What conditions does trial NCT06006247 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT06006247?
The interventions under investigation include: Placebo (DRUG), CVN424 150 mg (DRUG).
Who is sponsoring clinical trial NCT06006247?
This trial is sponsored by Cerevance Beta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06006247 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.